A Centers for Disease Control and Prevention (CDC) advisory committee is recommending that the Johnson & Johnson COVID-19 vaccine resume rollout, but include new language on the product's emergency use authorization (EUA) warning remote risks of serious blood clots. The Advisory Committee on Immunization Practices held the vote Friday after the FDA and CDC had recommended a pause in the Johnson & Johnson COVID-19 vaccine rollout last week due to several instances of a rare, severe blood clot amid a backdrop of over 7 million recipients.

The vote was 10 to 4.

One committee member abstained.